Prenetics Global is trading at $19.20, down 5.23%, as broad market weakness coincided with the October 16 decline; no verified company-specific announcement explaining it surfaced.
- The latest company release identified: the October 12 IM8-NBA partnership announcement.
- The Nasdaq fell 2.40% and the S&P 500 fell 1.36%, alongside a reported technology sell-off and risk-off rotation. Biotech shares were under pressure, with XBI down 2.06% during the regular session. These moves offer context, not proof of a sole cause.